Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy

American Journal of Cardiology

Volumn 106, Issue 3, 2010, Pages 360-368

  Turer, Aslan T ^a   Hill, Joseph A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION;

ACUTE HEART INFARCTION; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; HEART ARREST; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEART PROTECTION; HEART SURGERY; IMMUNE SYSTEM; ISCHEMIC PRECONDITIONING; LEUKOCYTE; MITOCHONDRION; MUSCLE CELL; PATHOGENESIS; PRESSURE; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SARCOPLASMIC RETICULUM;

CARDIAC SURGICAL PROCEDURES; HEART ARREST, INDUCED; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RISK FACTORS;

EID: 77955444881     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.03.032     Document Type: Review

References (135)

1. D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone, T.B. Ferguson, E. Ford, K. Furie, C. Gillespie, A. Go, K. Greenlund, N. Haase, S. Hailpern, P.M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M.M. McDermott, J. Meigs, D. Mozaffarian, M. Mussolino, G. Nichol, V. Roger, W. Rosamond, R. Sacco, P. Sorlie, R. Stafford, T. Thom, S. Wasserthiel-Smoller, N.D. Wong, and J. Wylie-Rosett Heart disease and stroke statistics - 2010 update A report from the American Heart Association Circulation 121 2009 e1 e170
2. R.B. Jennings, H.M. Sommers, G.A. Smyth, H.A. Flack, and H. Linn Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog Arch Pathol 70 1960 68 78
3. E. Braunwald, and R.A. Kloner Myocardial reperfusion: a double-edged sword? J Clin Invest 76 1985 1713 1719
4. C.E. Murry, R.B. Jennings, and K.A. Reimer Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Circulation 74 1986 1124 1136
5. D.J. Hausenloy, A. Tsang, M.M. Mocanu, and D.M. Yellon Ischemic preconditioning protects by activating prosurvival kinases at reperfusion Am J Physiol Heart Circ Physiol 288 2005 H971 H976
6. J.M. Bond, B. Herman, and J.J. Lemasters Protection by acidotic pH against anoxia/reoxygenation injury to rat neonatal cardiac myocytes Biochem Biophys Res Commun 179 1991 798 803
7. J.J. Lemasters, J.M. Bond, E. Chacon, I.S. Harper, S.H. Kaplan, H. Ohata, D.R. Trollinger, B. Herman, and W.E. Cascio The pH paradox in ischemia-reperfusion injury to cardiac myocytes EXS 76 1996 99 114
8. + exchange Circ Res 65 1989 1045 1056
9. L.R. Bush, J.L. Romson, J.L. Ash, and B.R. Lucchesi Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs J Cardiovasc Pharmacol 4 1982 285 296
10. E.F. du Toit, and L.H. Opie Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion Circ Res 70 1992 960 967
11. S. Krause, and M.L. Hess Characterization of cardiac sarcoplasmic reticulum dysfunction during short-term, normothermic, global ischemia Circ Res 55 1984 176 184
12. P. Kaplan, M. Hendrikx, M. Mattheussen, K. Mubagwa, and W. Flameng Effect of ischemia and reperfusion on sarcoplasmic reticulum calcium uptake Circ Res 71 1992 1123 1130
13. 2+ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts J Clin Invest 79 1987 950 961
14. W.G. Nayler The role of calcium in the ischemic myocardium Am J Pathol 102 1981 262 270
15. A.N.E. Zimmerman, W. Daems, W.C. Hulsmann, J. Snijder, E. Wisse, and D. Durrer Morphological changes of heart muscle caused by successive perfusion with calcium-free and calcium-containing solutions (calcium paradox) Cardiovasc Res 1 1967 201 209
16. S. Orrenius, B. Zhivotovsky, and P. Nicotera Regulation of cell death: the calcium-apoptosis link Nat Rev Mol Cell Biol 4 2003 552 565
17. 2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion Am J Physiol Heart Circ Physiol 290 2006 H2024 H2034
18. K.G. Rajesh, S. Sasaguri, R. Suzuki, and H. Maeda Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression Am J Physiol Heart Circ Physiol 285 2003 H2171 H2178
19. 2+ FEBS J 272 2005 3593 3601
20. S.L. Thompson-Gorman, and J.L. Zweier Evaluation of the role of xanthine oxidase in myocardial reperfusion injury J Biol Chem 265 1990 6656 6663
21. Y. Xia, and J.L. Zweier Substrate control of free radical generation from xanthine oxidase in the postischemic heart J Biol Chem 270 1995 18797 18803
22. D.B. Zorov, M. Juhaszova, Y. Yaniv, H.B. Nuss, S. Wang, and S.J. Sollott Regulation and pharmacology of the mitochondrial permeability transition pore Cardiovasc Res 83 2009 213 225
23. D.B. Zorov, C.R. Filburn, L.O. Klotz, J.L. Zweier, and S.J. Sollott Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes J Exp Med 192 2000 1001 1014
24. K.E. Loke, P.I. McConnell, J.M. Tuzman, E.G. Shesely, C.J. Smith, C.J. Stackpole, C.I. Thompson, G. Kaley, M.S. Wolin, and T.H. Hintze Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption Circ Res 84 1999 840 845
25. M.W. Radomski, R.M. Palmer, and S. Moncada Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium Lancet 2 1987 1057 1058
26. X.L. Ma, A.S. Weyrich, D.J. Lefer, and A.M. Lefer Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium Circ Res 72 1993 403 412
27. J.S. Beckman, T.W. Beckman, J. Chen, P.A. Marshall, and B.A. Freeman Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide Proc Natl Acad Sci U S A 87 1990 1620 1624
28. P. Wang, and J.L. Zweier Measurement of nitric oxide and peroxynitrite generation in the postischemic heart Evidence for peroxynitrite-mediated reperfusion injury J Biol Chem 271 1996 29223 29230
29. Y. Matsui, H. Takagi, X. Qu, M. Abdellatif, H. Sakoda, T. Asano, B. Levine, and J. Sadoshima Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy Circ Res 100 2007 914 922
30. Z.V. Wang, B.A. Rothermel, and J.A. Hill Autophagy in hypertensive heart disease J Biol Chem 285 2010 8509 8514
31. W. Chao Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart Am J Physiol Heart Circ Physiol 296 2009 H1 H12
32. M.N. Busche, V. Pavlov, K. Takahashi, and G.L. Stahl Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin Am J Physiol Heart Circ Physiol 297 2009 H1853 H1859
33. S.K. Shernan, and C.D. Collard Role of the complement system in ischaemic heart disease: potential for pharmacological intervention BioDrugs 15 2001 595 607
34. Z. Yang, Y.J. Day, M.C. Toufektsian, Y. Xu, S.I. Ramos, M.A. Marshall, B.A. French, and J. Linden Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes Circulation 114 2006 2056 2064
35. M. Kobara, N. Sunagawa, M. Abe, N. Tanaka, H. Toba, H. Hayashi, N. Keira, T. Tatsumi, H. Matsubara, and T. Nakata Apoptotic myocytes generate monocyte chemoattractant protein-1 and mediate macrophage recruitment J Appl Physiol 104 2008 601 609
36. R.A. Kloner, C.E. Ganote, and R.B. Jennings The "no-reflow" phenomenon after temporary coronary occlusion in the dog J Clin Invest 54 1974 1496 1508
37. D. Brosh, A.R. Assali, A. Mager, A. Porter, D. Hasdai, I. Teplitsky, E. Rechavia, S. Fuchs, A. Battler, and R. Kornowski Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality Am J Cardiol 99 2007 442 445
38. J.P. Henriques, F. Zijlstra, A.W. van 't Hof, M.J. de Boer, J.H. Dambrink, M. Gosselink, J.C. Hoorntje, and H. Suryapranata Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade Circulation 107 2003 2115 2119
39. C.M. Gibson, C.P. Cannon, S.A. Murphy, S.J. Marble, H.V. Barron, and E. Braunwald Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction Circulation 105 2002 1909 1913
40. G. Niccoli, F. Burzotta, L. Galiuto, and F. Crea Myocardial no-reflow in humans J Am Coll Cardiol 54 2009 281 292
41. A. Okamura, H. Ito, K. Iwakura, S. Kawano, K. Inoue, Y. Maekawa, T. Ogihara, and K. Fujii Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device J Am Coll Cardiol 45 2005 212 215
42. H. Ito No-reflow phenomenon and prognosis in patients with acute myocardial infarction Nat Clin Pract Cardiovasc Med 3 2006 499 506
43. D.E. Attarian, R.N. Jones, W.D. Currie, R.C. Hill, J.D. Sink, C.O. Olsen, W.R. Chitwood Jr, and A.S. Wechsler Characteristics of chronic left ventricular hypertrophy induced by subcoronary valvular aortic stenosis I. Myocardial blood flow and metabolism J Thorac Cardiovasc Surg 81 1981 382 388
44. P.G. Anderson, M.F. Allard, G.D. Thomas, S.P. Bishop, and S.B. Digerness Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts Circ Res 67 1990 948 959
45. P. Ferdinandy, Z. Szilvassy, and G.F. Baxter Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon? Trends Pharmacol Sci 19 1998 223 229
46. D. Feuvray, and G.D. Lopaschuk Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased Cardiovasc Res 34 1997 113 120
47. C. Di Filippo, R. Marfella, S. Cuzzocrea, E. Piegari, P. Petronella, D. Giugliano, F. Rossi, and M. D'Amico Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion Diabetes 54 2005 803 810
48. J. Neckar, B. Ostadal, and F. Kolar Myocardial infarct size-limiting effect of chronic hypoxia persists for five weeks of normoxic recovery Physiol Res 53 2004 621 628
49. C. Chen, L. Chen, J.T. Fallon, L. Ma, L. Li, L. Bow, D. Knibbs, R. McKay, L.D. Gillam, and D.D. Waters Functional and structural alterations with 24-hour myocardial hibernation and recovery after reperfusion A pig model of myocardial hibernation Circulation 94 1996 507 516
50. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 2007 1121 1135
51. K.W. Mahaffey, J.A. Puma, N.A. Barbagelata, M.F. DiCarli, M.A. Leesar, K.F. Browne, P.R. Eisenberg, R. Bolli, A.C. Casas, V. Molina-Viamonte, C. Orlandi, R. Blevings, R.J. Gibbons, R.M. Califf, and C.B. Granger Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial J Am Coll Cardiol 34 1999 1711 1720
52. A.R. Assali, S. Sdringola, M. Ghani, A.E. Denkats, A. Yepes, G.P. Hanna, G. Schroth, K. Fujise, H.V. Anderson, R.W. Smalling, and O.R. Rosales Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon Catheter Cardiovasc Interv 51 2000 27 31
53. M.G. Stoel, K.M. Marques, C.C. de Cock, J.G. Bronzwaer, B.C. von, and F. Zijlstra High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study Catheter Cardiovasc Interv 71 2008 283 289
54. V. Pasceri, C. Pristipino, F. Pelliccia, A. Granatelli, G. Speciale, A. Roncella, B. Pironi, M. Capasso, and G. Richichi Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction Am J Cardiol 95 2005 1358 1361
55. H.J. Wang, P.H. Lo, J.J. Lin, H. Lee, and J.S. Hung Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction Catheter Cardiovasc Interv 63 2004 171 176
56. G. Amit, C. Cafri, S. Yaroslavtsev, S. Fuchs, O. Paltiel, A. Bu-Ful, J.M. Weinstein, A. Wolak, R. Ilia, and D. Zahger Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction A randomized, double-blind, placebo-controlled clinical trial Am Heart J 152 2006 814 887
57. C. Barcin, A.E. Denktas, R.J. Lennon, L. Hammes, S.T. Higano, D.R. Holmes Jr, K.N. Garratt, and A. Lerman Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon Catheter Cardiovasc Interv 61 2004 484 491
58. W.K. Laskey Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study Catheter Cardiovasc Interv 65 2005 361 367
59. P. Staat, G. Rioufol, C. Piot, Y. Cottin, T.T. Cung, I. L'Huillier, J.F. Aupetit, E. Bonnefoy, G. Finet, X. Andre-Fouet, and M. Ovize Postconditioning the human heart Circulation 112 2005 2143 2148
60. W.K. Laskey, S. Yoon, N. Calzada, and M.J. Ricciardi Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning Catheter Cardiovasc Interv 72 2008 212 220
61. C. Piot, P. Croisille, P. Staat, H. Thibault, G. Rioufol, N. Mewton, R. Elbelghiti, T.T. Cung, E. Bonnefoy, D. Angoulvant, C. Macia, F. Raczka, C. Sportouch, G. Gahide, G. Finet, X. Andre-Fouet, D. Revel, G. Kirkorian, J.P. Monassier, G. Derumeaux, and M. Ovize Effect of cyclosporine on reperfusion injury in acute myocardial infarction N Engl J Med 359 2008 473 481
62. A.H. Olivencia-Yurvati, J.L. Blair, M. Baig, and R.T. Mallet Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass J Cardiothorac Vasc Anesth 17 2003 715 720
63. I. Uyar, D. Mansuroglu, K. Kirali, V. Erentug, N.U. Bozbuga, G. Uysal, and C. Yakut Aspartate and glutamate-enriched cardioplegia in left ventricular dysfunction J Card Surg 20 2005 337 344
64. P. Modi, M.S. Suleiman, B. Reeves, A. Pawade, A.J. Parry, G.D. Angelini, and M. Caputo Myocardial metabolic changes during pediatric cardiac surgery: a randomized study of 3 cardioplegic techniques J Thorac Cardiovasc Surg 128 2004 67 75
65. S.R. Walsh, T.Y. Tang, P. Kullar, D.P. Jenkins, D.P. Dutka, and M.E. Gaunt Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials Eur J Cardiothorac Surg 34 2008 985 994
66. A. Fabbri, J. Manfredi, C. Piccin, G. Soffiati, M.R. Carta, E. Gasparotto, and G. Nardon Systemic leukocyte filtration during cardiopulmonary bypass Perfusion 16 suppl 2001 11 18
67. J. Koskenkari, J. Rimpilainen, F. Biancari, H.M. Surcel, P. Kaukoranta, K. Kiviluoma, T. Ala-Kokko, and T. Juvonen Leukocyte depleting filter attenuates myocardial injury during elective coronary artery bypass surgery Scand Cardiovasc J 39 2005 358 368
68. S.R. Leal-Noval, R. Amaya, A. Herruzo, A. Hernandez, A. Ordonez, A. Marin-Niebla, and P. Camacho Effects of a leukocyte depleting arterial line filter on perioperative morbidity in patients undergoing cardiac surgery: a controlled randomized trial Ann Thorac Surg 80 2005 1394 1400
69. O.J. Liakopoulos, J.D. Schmitto, S. Kazmaier, A. Brauer, M. Quintel, F.A. Schoendube, and H. Dorge Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery Ann Thorac Surg 84 2007 110 119
70. M.P. Fillinger, A.J. Rassias, P.M. Guyre, J.H. Sanders, M. Beach, J. Pahl, R.B. Watson, P.K. Whalen, K.T. Yeo, and M.P. Yeager Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery J Cardiothorac Vasc Anesth 16 2002 163 169
71. P. Tassani, J.A. Richter, A. Barankay, S.L. Braun, C. Haehnel, P. Spaeth, H. Schad, and H. Meisner Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? J Cardiothorac Vasc Anesth 13 1999 165 172
72. S. De Hert, D. Vlasselaers, R. Barbe, J.P. Ory, D. Dekegel, R. Donnadonni, J.L. Demeere, J. Mulier, and P. Wouters A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery Anaesthesia 64 2009 953 960
73. M. Meco, S. Cirri, C. Gallazzi, G. Magnani, and D. Cosseta Desflurane preconditioning in coronary artery bypass graft surgery: a double-blinded, randomised and placebo-controlled study Eur J Cardiothorac Surg 32 2007 319 325
74. K. Julier, R. da Silva, C. Garcia, L. Bestmann, P. Frascarolo, A. Zollinger, P.G. Chassot, E.R. Schmid, M.I. Turina, L.K. von Segesser, T. Pasch, D.R. Spahn, and M. Zaugg Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study Anesthesiology 98 2003 1315 1327
75. E.D. Verrier, S.K. Shernan, K.M. Taylor, F. Van de Werf, M.F. Newman, J.C. Chen, M. Carrier, A. Haverich, K.J. Malloy, P.X. Adams, T.G. Todaro, C.F. Mojcik, S.A. Rollins, and J.H. Levy Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial JAMA 291 2004 2319 2327
76. L. Testa, W.J. Van Gaal, R. Bhindi, G.G. Biondi-Zoccai, A. Abbate, P. Agostoni, I. Porto, F. Andreotti, F. Crea, and A.P. Banning Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients J Thorac Cardiovasc Surg 136 2008 884 893
77. J.C. Tardif, M. Carrier, D.E. Kandzari, R. Emery, R. Cote, T. Heinonen, M. Zettler, V. Hasselblad, M.C. Guertin, and R.A. Harrington Effects of pyridoxal-5′-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study J Thorac Cardiovasc Surg 133 2007 1604 1611
78. J.H. Alexander, R.W. Emery Jr, M. Carrier, S.J. Ellis, R.H. Mehta, V. Hasselblad, P. Menasche, A. Khalil, R. Cote, E. Bennett-Guerrero, M.J. Mack, G. Schuler, R.A. Harrington, and J.C. Tardif Efficacy and safety of pyridoxal 5′-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial JAMA 299 2008 1777 1787
79. P. Theroux, B.R. Chaitman, N. Danchin, L. Erhardt, T. Meinertz, J.S. Schroeder, G. Tognoni, H.D. White, J.T. Willerson, A. Jessel Guard During Ischemia Against Necrosis (GUARDIAN) Investigators Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations Main results of the GUARDIAN trial Circulation 102 2000 3032 3038
80. S.W. Boyce, C. Bartels, R. Bolli, B. Chaitman, J.C. Chen, E. Chi, A. Jessel, D. Kereiakes, J. Knight, L. Thulin, and P. Theroux Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study J Thorac Cardiovasc Surg 126 2003 420 427
81. R.M. Mentzer Jr, C. Bartels, R. Bolli, S. Boyce, G.D. Buckberg, B. Chaitman, A. Haverich, J. Knight, P. Menasche, M.L. Myers, J. Nicolau, M. Simoons, L. Thulin, and R.D. Weisel Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study Ann Thorac Surg 85 2008 1261 1270
82. J.M. Leung, T. Stanley III, J. Mathew, P. Curling, P. Barash, M. Salmenpera, J.G. Reves, M. Hollenberg, D.T. Mangano SPI Research Group An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery Anesth Analg 78 1994 420 434
83. P. Menasche, W.R. Jamieson, W. Flameng, M.K. Davies Multinational Acadesine Study Group Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting Results of the first international multicenter study J Thorac Cardiovasc Surg 110 1995 1096 1106
84. Multicenter Study of Perioperative Ischemia (McSPI) Research Group Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery Anesthesiology 83 1995 658 673
85. D.T. Mangano, Y. Miao, I.C. Tudor, and C. Dietzel Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine J Am Coll Cardiol 48 2006 206 214
86. D.T. Mangano Multicenter Study of Perioperative Ischemia (McSPI) Research Group Effects of acadesine on myocardial infarction, stroke, and death following surgery A meta-analysis of the 5 international randomized trials JAMA 277 1997 325 332
87. V. Venugoapl, D.J. Hausenloy, A. Ludman, C. Di Salvo, S. Kolvekar, J. Yap, D. Lawrence, J. Bognolo, and D.M. Yellon Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial Heart 95 2009 1567 1571
88. D.P. Faxon, R.J. Gibbons, N.A. Chronos, P.A. Gurbel, F. Sheehan HALT-MI Investigators The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study J Am Coll Cardiol 40 2002 1199 1204
89. P.W. Armstrong, C.B. Granger, P.X. Adams, C. Hamm, D. Holmes Jr, W.W. O'Neill, T.G. Todaro, A. Vahanian, F. Van de Werf APEX AMI Investigators Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 2007 43 51
90. U. Zeymer, H. Suryapranata, J.P. Monassier, G. Opolski, J. Davies, G. Rasmanis, G. Linssen, U. Tebbe, R. Schröder, R. Tiemann, T. Machnig, K.L. Neuhaus ESCAMI Investigators The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial J Am Coll Cardiol 38 2001 1644 1650
91. W.E. Boden, W.H. van Gilst, R.G. Scheldewaert, I.R. Starkey, M.F. Carlier, D.G. Julian, A. Whitehead, M.E. Bertrand, J.J. Col, O.L. Pedersen, K.I. Lie, J.P. Santoni, and K.M. Fox Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (INTERCEPT) Lancet 355 2000 1751 1756
92. S. Umemura, S. Nakamura, T. Sugiura, Y. Tsuka, K. Fujitaka, S. Yoshida, M. Baden, and T. Iwasaka The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention Nucl Med Commun 27 2006 247 254
93. K. Vijayalakshmi, V.J. Whittaker, B. Kunadian, J. Graham, R.A. Wright, J.A. Hall, A. Sutton, and M.A. de Belder Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes Heart 92 2006 1278 1284
94. W. Guan, T. Osanai, T. Kamada, H. Hanada, H. Ishizaka, H. Onodera, A. Iwasa, N. Fujita, S. Kudo, T. Ohkubo, and K. Okumura Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction J Cardiovasc Pharmacol 41 2003 699 705
95. H. Ishii, S. Ichimiya, M. Kanashiro, T. Amano, K. Imai, T. Murohara, and T. Matsubara Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction Circulation 112 2005 1284 1288
96. A.V. Guffin, R.A. Kates, G.W. Holbrook, E.L. Jones, and J.A. Kaplan Verapamil and myocardial preservation in patients undergoing coronary artery bypass surgery Ann Thorac Surg 41 1986 587 591
97. G.S. Weinstein, P.S. Rao, and D.H. Tyras Reduction of myocardial injury with verapamil before aortic cross-clamping Ann Thorac Surg 49 1990 419 423
98. R. Seitelberger, W. Hannes, M. Gleichauf, M. Keilich, M. Christoph, and R. Fasol Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting J Thorac Cardiovasc Surg 107 1994 811 821
99. Clinical study to examine the effects of erythropoietin on left ventricular function after acute myocardial infarction (HEBEIII) http://clinicaltrials.gov/ct2/show/NCT00449488 Accessed on January 5, 2010
100. EPOMI study: Erythropoietin in Myocardial Infarction http:// clinicaltrials.gov/ct2/show/NCT00648089 Accessed on January 5, 2010
101. REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Late Myocardial Infarction http://clinicaltrials.gov/ct2/ show/NCT00378352 Accessed on January 5, 2010
102. G.L. Wright, P. Hanlon, K. Amin, C. Steenbergen, E. Murphy, and M.O. Arcasoy Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury FASEB J 18 2004 1031 1033
103. A.F. Tramontano, R. Muniyappa, A.D. Black, M.C. Blendea, I. Cohen, L. Deng, J.R. Sowers, M.V. Cutaia, and N. El-Sherif Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway Biochem Biophys Res Commun 308 2003 990 994
104. E. Gao, M. Boucher, J.K. Chuprun, R.H. Zhou, A.D. Eckhart, and W.J. Koch Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart Am J Physiol Heart Circ Physiol 293 2007 H60 H68
105. L. Calvillo, R. Latini, J. Kajstura, A. Leri, P. Anversa, P. Ghezzi, M. Salio, A. Cerami, and M. Brines Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling Proc Natl Acad Sci U S A 100 2003 4802 4806
106. C. Toma, D.P. Letts, M. Tanabe, J. Gorcsan III, and P.J. Counihan Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion J Mol Cell Cardiol 43 2007 130 136
107. C. Schneider, K. Jaquet, R. Malisius, S. Geidel, E. Bahlmann, S. Boczor, T. Rau, M. Antz, K.H. Kuck, and K. Krause Attenuation of cardiac remodelling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium Eur Heart J 28 2007 499 509
108. F. Prunier, O. Pfister, L. Hadri, L. Liang, F. Del Monte, R. Liao, and R.J. Hajjar Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells Am J Physiol Heart Circ Physiol 292 2007 H522 H529
109. A. Abbate, F.N. Salloum, E. Vecile, A. Das, N.N. Hoke, S. Straino, G.G. Biondi-Zoccai, J.E. Houser, I.Z. Qureshi, E.D. Ownby, E. Gustini, L.M. Biasucci, A. Severino, M.C. Capogrossi, G.W. Vetrovec, F. Crea, A. Baldi, R.C. Kukreja, and A. Dobrina Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction Circulation 117 2008 2670 2683
110. Anakinra to prevent post-infarction remodeling (VCU-ART) http://clinicaltrials.gov/ct2/show/NCT00789724 Accessed on January 5, 2010
111. L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, D. Elahi, and R.P. Shannon Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
112. Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI (POSTCON II) http://clinicaltrials.gov/ct2/show/NCT00835848 Accessed on January 5, 2010
113. G.S. Liu, J. Thornton, D.M. Van Winkle, A.W.H. Stanley, R.A. Olsson, and J.M. Downey Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart Circulation 84 1991 350 356
114. X.-M. Yang, S. Philipp, J.M. Downey, and M.V. Cohen Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation Basic Res Cardiol 100 2005 57 63
115. H. Kin, A.J. Zatta, M.T. Lofye, B.S. Amerson, M.E. Halkos, F. Kerendi, Z.-Q. Zhao, R.A. Guyton, J.P. Headrick, and J. Vinten-Johansen Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine Cardiovasc Res 67 2005 124 133
116. J. Ki, R. McIntosh, X. Shen, S. Lee, G. Chanoit, H. Criswell, D.A. Zvara, and Z. Xu Adenosine A2a and A2b receptors work in concert to induce a strong protection against reperfusion injury in rat hearts J Mol Cell Cardiol 47 2009 684 690
117. R.H. Lie, J.M. Hasenkam, T.T. Nielsen, R. Poulsen, and E. Sloth Post-conditioning reduces infarct size in an open-chest porcine acute ischemia-reperfusion model Acta Anaesthesiol Scand 52 2008 1188 1193
118. H. Kin, Z.Q. Zhao, H.Y. Sun, N.P. Wang, J.S. Corvera, M.E. Halkos, F. Kerendi, R.A. Guyton, and J. Vinten-Johansen Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion Cardiovasc Res 62 2004 74 85
119. Z.Q. Zhao, J.S. Corvera, M.E. Halkos, F. Kerendi, N.P. Wang, R.A. Guyton, and J. Vinten-Johansen Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning Am J Physiol Heart Circ Physiol 285 2003 H579 H588
120. J. Vinten-Johansen, Z.Q. Zhao, R. Jiang, A.J. Zatta, and G.P. Dobson Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury J Appl Physiol 103 2007 1441 1448
121. M.V. Cohen, X.M. Yang, and J.M. Downey The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis Circulation 115 2007 1895 1903
122. M.V. Cohen, X.M. Yang, and J.M. Downey Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success Basic Res Cardiol 103 2008 464 471
123. S.M. Weman, P.J. Karhunen, A. Penttila, A.A. Jarvinen, and U.S. Salminen Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting Ann Thorac Surg 70 2000 807 812
124. G.W. Moore, and G.M. Hutchins Coronary artery bypass grafts in 109 autopsied patients Statistical analysis of graft and anastomosis patency and regional myocardial injury JAMA 246 1981 1785 1789
125. B.H. Bulkely, and G.M. Hutchins Myocardial consequences of coronary artery bypass graft surgery The paradox of necrosis in areas of revascularization Circulation 56 1977 906 913
126. K. Klatte, B.R. Chaitman, P. Theroux, J.A. Gavard, K. Stocke, S. Boyce, C. Bartels, B. Keller, and A. Jessel Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial J Am Coll Cardiol 38 2001 1070 1077
127. M.A. Costa, R.G. Carere, S.V. Lichtenstein, D.P. Foley, V. de Valk, W. Lindenboom, P.C. Roose, T.R. van Geldorp, C. Macaya, J.L. Castanon, F. Fernandez-Avilez, J.H. Gonzales, G. Heyer, F. Unger, and P.W. Serruys Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS) Circulation 104 2001 2689 2693
128. A.D. Shaw, M. Stafford-Smith, W.D. White, B. Phillips-Bute, M. Swaminathan, C. Milano, I.J. Welsby, S. Aronson, J.P. Mathew, E.D. Peterson, and M.F. Newman The effect of aprotinin on outcome after coronary-artery bypass grafting N Engl J Med 358 2008 784 793
129. S. Schneeweiss, J.D. Seeger, J. Landon, and A.M. Walker Aprotinin during coronary-artery bypass grafting and risk of death N Engl J Med 358 2008 771 783
130. D.A. Fergusson, P.C. Hebert, C.D. Mazer, S. Fremes, C. MacAdams, J.M. Murkin, K. Teoh, P.C. Duke, R. Arellano, M.A. Blajchman, J.S. Bussieres, D. Cote, J. Karski, R. Martineau, J.A. Robblee, M. Rodger, G. Wells, J. Clinch, and R. Pretorius A comparison of aprotinin and lysine analogues in high-risk cardiac surgery N Engl J Med 358 2008 2319 2331
131. D.E. Kandzari, J.P. Dery, P.W. Armstrong, D.A. Douglas, M.E. Zettler, G.K. Hidinger, A.D. Friesen, and R.A. Harrington MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury Expert Opin Investig Drugs 14 2005 1435 1442
132. K. Mullane Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury Cardiovasc Res 27 1993 43 47
133. H.E. Gruber, M.E. Hoffer, D.R. McAllister, P.K. Laikind, T.A. Lane, G.W. Schmid-Schoenbein, and R.L. Engler Increased adenosine concentration in blood from ischemic myocardium by AICA riboside Effects on flow, granulocytes, and injury Circulation 80 1989 1400 1411
134. K. Forster, I. Paul, N. Solenkova, A. Staudt, M.V. Cohen, J.M. Downey, S.B. Felix, and T. Krieg NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase Basic Res Cardiol 101 2006 319 326
135. The effect of acadesine on reducing cardiovascular and cerebrovascular adverse events in coronary artery bypass graft (CABG) surgery (study P05633AM1) (RED-CABG) http://clinicaltrials.gov/ct2/show/NCT00872001 Accessed on January 5, 2010